Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters

By /

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging trends” in efficacy.

Scroll to Top